Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 -2.18%95 EV-to-FCF is 28.01 as of Aug. 27, 2026, which is 49% below its 10-year median of 55.23. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 409 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks worse than 57.46% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Autobio Diagnostics Co's Enterprise Value is ¥18,004 Mil.
Autobio Diagnostics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ¥643 Mil. Therefore, Autobio Diagnostics Co's EV-to-FCF for today is 28.01.
The historical rank and industry rank for Autobio Diagnostics Co's EV-to-FCF or its related term are showing as below:
SHSE:603658'
s EV-to-FCF Range Over the Past 10 Years
Min: -2513.7 Med: 55.23 Max: 1029.74
Current: 28.01
During the past 13 years, the highest EV-to-FCF of Autobio Diagnostics Co was 1029.74. The lowest was -2513.70. And the median was 55.23.
SHSE:603658's EV-to-FCF is ranked worse than 57.46% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.43
vs SHSE:603658: 28.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Autobio Diagnostics Co (SHSE:603658) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Autobio Diagnostics Co's PE Ratio (TTM) for today is calculated as:
Autobio Diagnostics Co's share price for today is ¥32.68.
Autobio Diagnostics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603658 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's EV-to-FCF falls into.
Autobio Diagnostics Co's current Enterprise Value is ¥18,004 Mil.
Autobio Diagnostics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥643 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co (SHSE:603658) has a EV-to-FCF of 28.01 as of Aug. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Autobio Diagnostics Co and its competitors. This is 49% below median its historical median of 55.23. According to the industry distribution chart, Autobio Diagnostics Co ranks #235 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 57.5%.
Is Autobio Diagnostics Co's EV-to-FCF too high?
Autobio Diagnostics Co's current EV-to-FCF of 28.01 is 49% below median its 10-year median of 55.23. The Medical Devices & Instruments industry median EV-to-FCF is 24.43. Autobio Diagnostics Co's value of 28.01 is 14.7% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #235 out of 409 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #235 out of 409 companies for EV-to-FCF. This places Autobio Diagnostics Co in the lower half of its industry. The industry median EV-to-FCF is 24.43. Autobio Diagnostics Co's value of 28.01 is 14.7% above this benchmark. While the company's 10-year median is 55.23 vs. the industry median of 24.43, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.43, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current EV-to-FCF of 28.01 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current EV-to-FCF is 28.01, which is 49% below median its own 10-year median of 55.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.68 — trading 19.2% below its estimated fair value. The current EV-to-FCF is 28.01, which is 49% below median its 10-year median of 55.23 and 14.7% above the Medical Devices & Instruments industry median of 24.43. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current EV-to-FCF is 28.01 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.68 is trading 19.2% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
EV-to-FCF: 28.01 (49% below median its 10-year median of 55.23)
GF Value™: ¥40.43 vs. price of ¥32.68 (19.2% below fair value)
Industry Position: 14.7% above the Medical Devices & Instruments median (#235 of 409)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
